Adolor and Pfizer entered into worldwide co-development agreement to develop and commercialize Adolor’s ADL5859 which is in phase 2 clinical trials for treating inflammatory pain associated with rheumatoid arthritis and acute post-dental surgery pain and ADL5747 which is in preclinical development for treating pain. The deal would worth up to US$264.4 M to Adolor if specific milestones and sales targets are met.